Creating contingency plans against geopolitical uncertainty was a key theme at the 2024 Outsourcing in Clinical Trials and Clinical Trial Supply East Asia conference in Seoul.

The results from the Phase III trial found the LDL-C treatment to be well tolerated with a reduction in low-density lipoprotein cholesterol.

Vivoryon's VIVA-MIND trial echoed the disappointing AD findings of its VIVIAD trial but offers promise in treating kidney function.

The Phase I trial of the company’s SRSD107 siRNA therapy found the treatment to be safe and well tolerated in its first-in-human tests.

Enanta Pharmaceuticals has reported positive topline outcomes from a Phase II trial of zelicapavir for RSV in paediatric patients.

While treatments for chronic hand eczema are available, there is significant unmet need in long-term disease management and symptom control.

US-based pharmaceutical company MSD has published results from a Phase III trial of a potential combination therapy for ovarian cancer.

AbbVie has reported that the Phase III TEMPO-2 trial of tavapadon for early-stage Parkinson's disease met its primary endpoint.

A panel highlighted the importance of supply chain prioritisation at the Outsourcing in Clinical Trials and Clinical Trial Supply East Asia conference in Seoul.

BioAge Labs has halted the Phase II randomised STRIDES trial of azelaprag,following the observation of liver transaminitis in some patients.

The US company has launched dosing in Taiwan for its Phase II trial of LP-300. In the US, some patients saw 51% tumour reduction.

Novartis has reported positive topline outcomes from the multicentre Phase IIIB APPULSE-PNH trial of Fabhalta for treating adults with PNH.